Zambon, A Multinational Pharmaceutical Company, Announced That The Us Food And Drug Administration (Fda) Has Granted Breakthrough Therapy Designation To Colistimethate Sodium Powder For Nebulization Solution (Cms I-Neb) For The Reduction In The Incidence Of Pulmonary Exacerbations In Adult Patients With Non-Cystic Fibrosis Bronchiectasis (Ncfb) Colonized With P. Aeruginosa. Ncfb Is A Chronic, Progressive, And Irreversible Respiratory Disease. There Are No Approved Inhaled Treatments Currently Available For Patients With Bronchiectasis And Chronic P. Aeruginosa Colonization.The Breakthrough Therapy Designation Is Supported By Data From The Phase 3 Promis - I Study, Which Showed That Cms I-Neb Significantly Reduced The Annual Rate Of Exacerbations In Patients With Ncfb And P. Aeruginosa Chronic Infection, The Primary Endpoint Of The Trial. In Addition, The Trial Met Important Secondary Endpoints, Including Reduction Of Severe Exacerbations And Prolongation Of Time To First Exacerbation Compared To Placebo, And Also Improvement In Quality Of Life (Qol). The Treatment Was Demonstrated To Be Well Tolerated With Adverse Events Similar Between Groups. Data From The Phase 3 Trial Were Most Recently Presented At The European Respiratory Society (Ers) International Congress In September 2021.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!